CORT Key Stats
|Revenue (Quarterly YoY Growth)||149.7%|
|EPS Diluted (TTM)||-0.4614|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-46.01M|
|Gross Profit Margin (Quarterly)||98.48%|
|Profit Margin (Quarterly)||-414.0%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- CORCEPT THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 25
- CORCEPT THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 12
- Corcept Therapeutics' CEO Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Nov 9
- Narrower-than-Expected Loss at Corcept Nov 8
- Narrower-than-Expected Loss at Corcept - Analyst Blog Zacks Nov 8
- Corcept Therapeutics Announces Third Quarter 2013 Financial Results and Corporate Update noodls Nov 7
- U.S./Canada daily earnings hits & misses Nov 7 - 1820 ET Reuters Nov 7
- Corcept Therapeutics Announces Third Quarter 2013 Financial Results and Corporate Update Marketwired Nov 7
- Q3 2013 Corcept Therapeutics Inc Earnings Release - After Market Close Nov 7
- Corcept Therapeutics to Announce Third Quarter 2013 Financial Results and Host Conference Call noodls Nov 4
CORT Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Corcept Therapeutics is up 43.95% over the last year vs S&P 500 Total Return up 28.99%, Shire up 44.39%, and Jazz Pharmaceuticals up 129.1%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for CORT
Pro Strategies Featuring CORT
Did Corcept Therapeutics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Corcept Therapeutics Inc. is engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders.